Interference and correction of chylemia on blood cell analysis parameters in tumor patients

doi:10.3969/j.issn.1673-8640.2024.08.009

Abstract

Abstract:

Objective To analyze the influence of chylemia on blood cell analysis parameters in tumor patients，and to investigate the correction effect of plasma exchange on chylemia，so as to provide a reference for laboratory to accurately report the results of blood cell analysis. Methods From January 2022 to August 2023，54 whole blood samples of tumor patients who were confirmed to have chylemia were enrolled from the Department of Clinical Laboratory of Cancer Hospital and Shenzhen Hospital of Chinese Academy of Medical Sciences Peking Union Medical College. cencer of By blood cell analyzer，white blood cell （WBC） count，platelet（PLT） count，red blood cell（RBC） count，hemoglobin（HGB），hematocrit（HCT），mean corpuscular volume（MCV），mean corpuscular hemoglobin（MCH） and mean corpuscular hemoglobin concentration（MCHC） were determined before and after plasma exchange. With the instrument alarm “Turbidity/HGB Interf?” was eliminated，the MCHC returned to normal or stable levels，or it was consistent with historical results，the state of chylemia was corrected. The results were compared before and after correction. The clinical data of patients were collected to understand the source of chylemia samples. Results Chylemia samples were mainly collected from middle-aged and elderly patients with breast cancer，lung cancer，liver cancer and pancreatic cancer（37.04%，20/54）. WBC count，PLT count，HGB，MCH and MCHC before correction were higher than those after correction（P<0.05）. There was no statistical significance in RBC count，HCT and MCV before and after correction（P>0.05）. Conclusions Chylemia mainly affects the results of WBC count，PLT count，HGB，MCH and MCHC，and plasma exchange can eliminate the interference.

Key words: Chylemia, Blood cell analysis, Plasma exchange, Interference, Tumor

CLC Number:

R446.11

ZHANG Jialing, QI Jun. Interference and correction of chylemia on blood cell analysis parameters in tumor patients[J]. Laboratory Medicine, 2024, 39(8): 770-773.

Figures/Tables 1

References 12

[1]	李程琳, 刘艳石, 井娜, 等. 建立一种纠正乳糜血对血红蛋白及平均红细胞血红蛋白浓度检测干扰的新策略[J]. 中华检验医学杂志, 2023, 46(7):725-731.
[2]	李迎, 赵文吉. 高血脂患者乳糜血对血常规检测指标的影响[J]. 首都食品与医药, 2022, 29(5):77-79.
[3]	郑翠玲, 杨静, 程焱, 等. 血浆置换法纠正乳糜血对肿瘤患者全血细胞分析的影响[J]. 标记免疫分析与临床, 2020, 27(6):1074-1076.
[4]	黎炜杰, 陈群弟. 高血脂患者乳糜血对血常规生化检验指标的影响[J]. 中国处方药, 2019, 17(2):117-118.
[5]	李虹雁. 脂血对血液分析仪测定血常规指标的影响观察[J]. 世界最新医学信息文摘(连续型电子期刊), 2020, 20(35):123-124.
[6]	凌莉, 兰利梅, 胡斌, 等. 血浆置换法和公式校正法纠正乳糜血对仪器法测定血红蛋白影响的研究[J]. 中文科技期刊数据库(引文版)医药卫生, 2022(5):4.
[7]	陆英杰, 徐倩倩, 姜王庆, 等. MCHC用于发现和纠正血常规分析结果的价值探讨[J]. 检验医学, 2022, 37(8):754-756. DOI
[8]	修玮. 高血脂患者乳糜血对血常规检验指标的影响分析[J]. 东方药膳, 2021(1):101.
[9]	王克迪, 徐东江, 苏建荣. 血浆置换法和公式校正法纠正乳糜血对仪器法测定血红蛋白影响的探讨[J]. 现代检验医学杂志, 2017, 32(3):137-139.
[10]	BARNES P W, MCFADDEN S L, MACHIN S J, et al. The international consensus group for hematology review:suggested criteria for action following automated CBC and WBC differential analysis[J]. Lab Hematol, 2005, 11(2):83-90.
[11]	邵雨竹. 浅谈乳糜血样对血液分析仪测定血红蛋白结果的影响分析[J]. 中国医疗器械信息, 2021, 27(4):59-60.
[12]	中华医学会检验医学分会血液学与体液学学组. 血细胞分析报告规范化指南[J]. 中华检验医学杂志, 2020, 43(6):619-627.

项目	WBC计数/（×10⁹·L^-1）	PLT计数/ （×10⁹·L^-1）	RBC计数/（×10¹²·L^-1）	HGB/ （g·L^-1）	HCT/%	MCV/fL	MCH/pg	MCH/ （g·L^-1）
纠正前	8.97±5.69	203.00±119.00	3.22±0.86	115.00±29.00	29.10±7.30	91.00±6.50	36.00±3.20	397.00±36.00
纠正后	8.59±5.39	153.00±95.00	3.17±0.85	99.00±27.00	28.70±7.40	91.20±6.40	31.30±2.60	343.00±13.00
t值	2.485	6.207	1.860	8.966	1.676	-0.856	11.194	10.609
P值	0.016	<0.001	0.068	<0.001	0.100	0.396	<0.001	<0.001

项目	WBC计数/（×10⁹·L^-1）	PLT计数/ （×10⁹·L^-1）	RBC计数/（×10¹²·L^-1）	HGB/ （g·L^-1）	HCT/%	MCV/fL	MCH/pg	MCH/ （g·L^-1）
纠正前	8.97±5.69	203.00±119.00	3.22±0.86	115.00±29.00	29.10±7.30	91.00±6.50	36.00±3.20	397.00±36.00
纠正后	8.59±5.39	153.00±95.00	3.17±0.85	99.00±27.00	28.70±7.40	91.20±6.40	31.30±2.60	343.00±13.00
t值	2.485	6.207	1.860	8.966	1.676	-0.856	11.194	10.609
P值	0.016	<0.001	0.068	<0.001	0.100	0.396	<0.001	<0.001

[1]	XU Fei, CHEN Zhujun, YU Liang, ZHANG Jing, LU Renquan, GUO Lin, ZHUANG Yihui. Analysis of etiological characteristics and death risk factors of candidemia in tumor patients [J]. Laboratory Medicine, 2024, 39(9): 888-894.
[2]	LÜ Minmin, HUANG Ying, YU Lan, CAO Liting, ZENG Cuimin. Determinations of serum interferon regulatory factor 4 and soluble suppression of tumorigenicity 2 in patients with oral periimplantitis [J]. Laboratory Medicine, 2024, 39(8): 723-727.
[3]	GONG Jingkai, OU Yuanzhu, YU Xiaoxuan, GE Danhong, LIN Feiran. Influence of hemoglobin，bilirubin，chylomicrons and calcium dobesilate on 3 determination systems [J]. Laboratory Medicine, 2024, 39(8): 749-758.
[4]	WANG Xuexing, CHEN Chunmei, HE Yuan, CHU Jie, WEI Chunmei. Roles of thromboelastography and coagulation index in predicting venous thromboembolism in patients with tumors [J]. Laboratory Medicine, 2024, 39(5): 491-496.
[5]	ZHANG Han, GUO Lin, LU Renquan, CHEN Fuxiang. Clinical value and prospect of peripheral blood immune indexes in cancer patients [J]. Laboratory Medicine, 2024, 39(4): 311-316.
[6]	ZHANG Heng, ZHENG Hui, LU Renquan. Research progress on the regulation of regulatory T cells in ovarian cancer tumor microenvironment [J]. Laboratory Medicine, 2024, 39(4): 317-323.
[7]	LI Yue, TENG Xiaoyan, DING Siying, HU Liuping, DU Yuzhen. Predictive role of neutrophil-to-lymphocyte ratio for distant metastasis in solid tumor patients [J]. Laboratory Medicine, 2024, 39(4): 324-329.
[8]	XU Yunchuan, HUANGFU Yuchan, MA Yanhui. Effect of highly expressed IL-35 on Th1 and Th17 plasticity in colorectal cancer [J]. Laboratory Medicine, 2024, 39(4): 343-350.
[9]	WANG Rong, GAO Chunfang. Application progress of exosomal glycosylation in diagnosis and treatment of tumors [J]. Laboratory Medicine, 2024, 39(4): 404-409.
[10]	YANG Jing, LIU Huapeng, LIU Ni. Role of serum MyD88 and TRAF-6 combined determination in diagnosis and prognosis of severe acute respiratory tract infection in children [J]. Laboratory Medicine, 2024, 39(3): 237-242.
[11]	Beijing Medical Association Laboratory Medicine Branch, Shanghai Medical Association Laboratory Medicine Branch. Expert consensus on interference factors and solutions for immunological testing [J]. Laboratory Medicine, 2024, 39(12): 1131-1139.
[12]	HUANG Qian, SHEN Qin, HU Qiuyun, SUN Jing, WAN Pingyin. Predictive values of serum CTRP3 and DKK-1 levels for the occurrence of fractures in postmenopausal osteoporosis patients [J]. Laboratory Medicine, 2024, 39(10): 950-955.
[13]	LEI Ming, ZHAI Li, WEI Ying, LIN Yichen, GUO Mengyue. Application of nomogram model based on clinical characteristics and serum tumor markers in differential diagnosis of benign and malignant lung lesions [J]. Laboratory Medicine, 2024, 39(10): 956-962.
[14]	LAI Yuanyuan, HE Zhenye, SHEN Huaqing, LIN Yiteng, LIU Xijun, QI Jun, LIN Yongping. Roles of TAT，PIC and thromboelastography for assessing coagulation function in tumor patients [J]. Laboratory Medicine, 2024, 39(1): 43-46.
[15]	ZHOU Yunlan, SHEN Lisong. Clinical application and challenges of liquid biopsy biomarkers in non-small cell lung cancer [J]. Laboratory Medicine, 2023, 38(9): 807-811.